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The emergence of virulent Pseudomonas aeruginosa clones is a threat to cystic fibrosis (CF) patients globally.
Characterization of clonal P. aeruginosa strains is critical for an understanding of its clinical impact and
developing strategies to meet this problem. Two clonal strains (AES-1 and AES-2) are circulating within CF
centers in eastern Australia. In this study, phenotypic characteristics of 43 (14 AES-1, 5 AES-2, and 24
nonclonal) P. aeruginosa isolates were compared to gain insight into the properties of clonal strains. All 43
isolates produced bands of the predicted size in PCRs for vfr, rhlI, rhlR, lasA, lasB, aprA, rhlAB, and exoS genes;
42 were positive for lasI and lasR, and none had exoU. Thirty-seven (86%) isolates were positive in total protease
assays; on zymography, 24 (56%) produced elastase/staphylolysin and 22 (51%) produced alkaline protease.
Clonal isolates were more likely than nonclonal isolates to be positive for total proteases (P  0.02), to show
elastase and alkaline protease activity by zymography (P  0.04 and P  0.01, respectively), and to show
elastase activity by the elastin-Congo red assay (P  0.04). There were no other associations with genotype.
Overall, increasing patient age was associated with decreasing elastase activity (P  0.03). Thirty-two (74%)
isolates had at least one N-acylhomoserine lactone (AHL) by thin-layer chromatography. rhl-associated AHL
detection was associated with the production and level of total protease and elastase activity (all P < 0.01).
Thirty-three (77%) isolates were positive for ExoS by Western blot analysis, 35 (81%) produced rhamnolipids,
and 34 (79%) showed chitinase activity. Findings suggest that protease activity during chronic infection may
contribute to the transmissibility or virulence of these clonal strains.
Pseudomonas aeruginosa lung infection is a major determi-
nant of morbidity and mortality in cystic fibrosis (CF) patients
(16). The pathogenesis of P. aeruginosa infection depends on
multiple cell-associated and extracellular virulence factors in-
cluding proteases (elastase [LasB], alkaline protease [AprA],
and staphylolysin [LasA]), hemolysins (rhamnolipids), and tox-
ins such as exoenzyme S (ExoS) and exotoxin A (13). Proteases
contribute to pathogenesis in the lung through the induction of
tissue necrosis and inflammation, destruction of surface recep-
tors on neutrophils resulting in the inhibition of chemotaxis,
phagocytosis, and the oxidative burst and degradation of sur-
factant proteins (27, 32).
Many P. aeruginosa virulence factors, including the pro-
teases, are regulated by cell-to-cell communication systems
that rely on diffusible N-acylhomoserine lactones (AHLs) to
monitor population size in a process known as “quorum sens-
ing” (QS) (7, 31). P. aeruginosa has two AHL-regulated cir-
cuits: las, consisting of the transcriptional activator LasR and
the AHL synthase LasI, which directs the synthesis of N-
(3-oxododecanoyl)-L-homoserine lactone (OdDHL), and rhl,
consisting of RhlR and RhlI, which directs the synthesis of
N-butanoyl-L-homoserine lactone (BHL) and N-hexanoyl-L-
homoserine lactone (HHL) (44). The las circuit also regulates
the expression of the rhl circuit. A third, more recently de-
scribed cell-signaling system, MvfR (multiple virulence factor
R), regulates Pseudomonas quinolone signal (PQS) biosynthe-
sis and is intertwined with the las and rhl systems (31).
Early P. aeruginosa infections in lungs of CF patients are
typically intermittent. However, by the teenage years, up to
80% of CF patients have become chronically infected (16).
Longitudinal studies have shown that the organism adapts for
long-term survival in the CF lung by the down-regulation of
virulence factors required for acute infection, including the
proteases and the type III secretion system (20), and the up-
regulation of genes required for biofilm development (15).
It is widely accepted that most CF patients harbor unique
(nonclonal) P. aeruginosa strains acquired from the environ-
mental pool. However, over recent years, clonal strains have
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been identified among CF patients in several centers in the
United Kingdom (21, 36), Australia (2, 30), and Canada (S.
Aaron, personal communication). Two clonal strains, Austra-
lian epidemic strain 1 (AES-1) (otherwise known as m16, the
Melbourne epidemic strain [MES], or PI) and AES-2 (PII),
currently infect from 6% to 40% of CF patients in five clinics
in eastern Australia (2, 30). CF clonal strains have not been
isolated from the environment to date, suggesting person-to-
person transmission, but acquisition from a common source
has not been excluded.
There is now consensus among the international CF com-
munity that the emergence of clonal strains poses a potential
major threat to patients’ well-being. With few exceptions,
clonal P. aeruginosa strains identified in CF clinics in Australia
and overseas have been associated with increased virulence
compared with unique strains. This increased virulence is not
fully explained by greater antibiotic resistance. AES-1 has been
associated with the unexpected deaths of five children with CF
who were under 5 years of age, raising particular concern over
its virulence in young children (3). Subsequently, patients with
the AES-1 strain have been shown to have lower lung function
and increased hospitalizations compared with those with
unique strains. Patients with AES-2 tend to be younger and to
have significantly lower pulmonary function (30). Transmission
of AES-1 to a patient with non-CF bronchiectasis has been
associated with rapidly declining clinical course, causing fur-
ther concern (33).
Insight into the properties of clonal strains is critical for the
development of effective strategies to address this problem.
The CF Liverpool epidemic strain (LES) has shown high levels
of expression of virulence factors, including elastase and staph-
ylolysin, associated with the premature activation of QS sys-
tems (34), and a virulent epidemic clone isolated from patients
with microbial keratitis has been characterized by high activi-
ties of an elastase variant (26). Our previous study of AES-1,
AES-2, and nonclonal P. aeruginosa isolates from subjects with
CF showed that clonal isolates were more likely to have pro-
tease IV activity than nonclonal isolates (40). Enhanced pro-
tease IV activity may promote tissue destruction and inflam-
mation and facilitate host-to-host spread. The major aim of
this study was to gain further insight into properties that me-
diate increased infectivity or virulence in our clonal P. aerugi-
nosa strains.
MATERIALS AND METHODS
Bacterial strains and culture conditions. Investigations were carried out using
43 P. aeruginosa isolates from the sputa of 43 patients attending the adult Royal
Prince Alfred Hospital (RPAH) CF Clinic, Sydney, Australia, between 2001 and
2004. The male-to-female ratio of the 43 patients was 21:22. The mean age was
27 years, and the age range was 18 to 58 years (Table 1). These values are
consistent with those for the RPAH CF Clinic population as a whole. The study
was approved by the Institutional Ethics Committee (approval X02-0320), and
subjects provided informed consent for the work. All patients had been chron-
ically infected with P. aeruginosa for a minimum of 4 years. Eighteen of the 43
(42%) isolates were derived from sputa collected at the time of exacerbation,
which is defined according to criteria established by Fuchs and colleagues (11),
and the remaining samples were obtained during routine clinic visits.
Isolates were routinely identified as being P. aeruginosa by growth on cetrimide
fucidin cephaloridine (Oxoid, Adelaide, Australia), acetamide, and Pseudosel
agars (both BBL, Liverpool, Australia); a positive oxidase reaction (MedVet
Science, Adelaide, Australia); growth on Columbia horse blood agar (Oxoid,
Adelaide, Australia) at 42°C; and resistance to 9-chloro-9-(4-diethylaminophe-
nyl)-10-phenylacridan (Dutec Diagnostics, Croydon, Australia). The identifica-
tion of isolates showing inconsistent results on these tests was confirmed using
the API 20E system. Genotyping using a restriction enzyme, SpeI, followed by
pulsed-field gel electrophoresis (PFGE) previously showed that two clones (des-
ignated AES-1 and AES-2) infected 40% and 6% of patients, respectively (P.
Tingpej, B. Rose, and C. Harbor, unpublished data). In this study, a clonal strain
was defined as one showing the same PFGE banding pattern (or a difference of
three bands or less) in three or more patients (43). Figure 1 shows DNA banding
patterns from AES-1 and AES-2 and nonclonal strains. DNA macrorestriction
patterns of AES-1 and AES-2 were found to share 67% similarity. Isolates used
in this study were randomly selected from the clonal and nonclonal pools in
proportion to their prevalence in the RPAH Clinic (14 AES-1, 5 AES-2, and 24
nonclonal isolates). The well-characterized wound-derived P. aeruginosa PAO1
(17) was included as a control. The AHL reporter strains Chromobacterium
violaceum CV026 and Agrobacterium tumefaciens A136 were used for AHL
assays, and Staphylococcus aureus strain ATCC 12600 was used for the staphylo-
lysin assay. Pseudomonas putida was used as a negative control for dot hybrid-
ization. For protease production, bacteria were grown in tryptone soya broth
(TSB; Oxoid, Adelaide, Australia) to late exponential phase (optical density at
600 nm [OD600]  1.6) at 37°C with rapid agitation. For ExoS Western blot
assays, strains were grown in TSB with 1 mM EGTA to an OD600 of 1.0 (20). For
AHL analyses, isolates were grown in TSB to late exponential phase or in AB
medium supplemented with 0.2% glucose to an OD600 of 1.0 (4, 12). A. tume-
faciens was grown in supplemented minimal A medium (A) (29), and C.
violaceum was grown in TSB, both at 30°C. Supernatants were collected and
filtered through a 0.22-m filter for protease, exoenzyme, and AHL detection.
Cell pellets were collected for gene amplification and dot hybridization studies.
Gene detection by PCR. DNA was extracted from cell pellets using the
microLYSIS kit (Microzone Ltd., Sussex, United Kingdom). PCRs were carried out
for the presence of five QS genes, vfr (5-TGTTCTTCCAGGAGCGTGG-3/3-
TCGCAAAATCACATCGAC-5), lasI, lasR, rhlI, and rhlR (45); three protease
genes, lasA (26), lasB, and aprA (45); the rhamnolipid gene rhlAB (45); and two
exotoxin genes, exoU and exoS (46), as previously described.
Dot blot hybridization. When PCR screening identified a strain that appar-
ently did not possess the lasI or lasR gene, dot blot hybridization was performed
to confirm the negative findings. Bacterial cell pellets were washed and resus-
pended in phosphate-buffered saline to an OD660 of 0.2. Digoxigenin-labeled
DNA probes for the lasI and lasR genes were generated from the PAO1 strain
using the primers for the PCRs (described above) according to the manufactur-
er’s instructions (Roche Diagnostics GmbH, Mannheim, Germany). Bacterial
cell suspensions were dot blotted onto a Hybond N membrane (General Elec-
tric Healthcare, Fairfield, CT). Blots were then hybridized using DIG EasyHyb
buffer (Roche Diagnostics GmbH, Mannheim, Germany). Hybrids were visual-
ized by standard alkaline phosphatase colorimetric detection. P. putida cells were
used as a negative control.
Exoprotease assays. (i) Total protease activity. Total protease activity was
determined as described previously (47). The protease activity was normalized to
the densities (OD600) of the cultures grown. Results were mean values  stan-
dard deviations (SD) from three replicate experiments carried out on three
separate occasions.
(ii) Zymography. Gelatin zymography for protease activity was carried out
using 10% polyacrylamide gels containing 0.1% (wt/vol) gelatin (Bio-Rad, Re-
gents Park, Australia). Unconcentrated supernatants were denatured in sodium
dodecyl sulfate (SDS) sample buffer. Following electrophoresis, gels were
washed in 2.5% Triton X-100 (Sigma-Aldrich, MO) to renature proteins, incu-
bated overnight at 37°C to induce protease activity, and then stained with 0.25%
Coomassie blue for 2 h with gentle shaking (10). Zymograms were imaged using
an Olympus (Tokyo, Japan) C-3040Zoom digital image acquisition system. Pro-
tease activities were represented by translucent bands against a Coomassie blue
background. All isolates were tested in triplicate on at least three occasions.
(iii) Elastase-specific activity. lasB-mediated elastolytic activity was deter-
mined by the elastin-Congo red (ECR) assay as described previously (35).
Uninoculated TSB was included as a negative control. All isolates were tested
in triplicate on at least two occasions. Results are represented as mean
values  SD.
(iv) Staphylolysin activity. lasA-mediated staphylolytic activity was determined
as described previously (23). All isolates were tested in triplicate at least twice,
and results shown are mean values  SD.
Chitinase activity. Chitinase activity was determined using the carboxymethyl-
chitin-remazol brilliant violet assay adapted from methods described by the
manufacturer (Loewe Biochemica, Munich, Germany) and Folders et al. (9).
Remazol brilliant violet liberated by chitinase activity was measured at 550 nm
and normalized to the cell density. Uninoculated TSB was used as a negative
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control. All isolates were tested in triplicate on at least two occasions, and results
are represented as mean values  SD.
Rhamnolipid production. The presence or absence of rhamnolipids was as-
sessed by the rhamnolipid-mediated alkane degradation method (49). PAO1
cultures grown under the same conditions as the test isolates and uninoculated
TSB were used as positive and negative controls, respectively.
Western blots for exoenzyme S. Supernatants were boiled for 5 min prior to
12% (wt/vol) nonreducing SDS-polyacrylamide gel electrophoresis (PAGE) at
100 mA for 2 h. Separated protein was electrophoretically blotted at 30 V onto
a Tris-glycine buffer-equilibrated polyvinylidene difluoride membrane (Immuno-
blot; Bio-Rad, Regents Park, Australia) using the Bio-Rad Mini-Transblot sys-
tem. Blots were blocked in 5% (wt/vol) bovine serum albumin in phosphate-
buffered saline, subsequently incubated overnight with chicken polyclonal
exoenzyme S antibody (Abcam, Cambridge, United Kingdom) at a 1:10,000
dilution, and developed in anti-chicken antibody alkaline phosphatase conjugate
(1:1,000) (Sigma-Aldrich, MO) using BCIP/NBT (5-bromo-4-chloro-3-indolyl
phosphate dipotassium–nitrotetrazolium blue chloride) solution (Sigma-Aldrich,
MO). Tests were carried out in duplicate on two different occasions.
Thin-layer chromatography. AHLs were identified by analytical thin-layer
chromatography (TLC) initially from bacteria grown in TSB as described previ-
ously for our studies of microbial keratitis (48). Chromatograms were developed
using C18 reversed-phase silica gel TLC plates (Whatmann, Clifton, NJ) with
TABLE 1. Characteristics of the study population
Isolate
group
Age
(yr)
Exacerbation
status Mucoidy
AHL productiona
(BHL/HHL/OHHL/ODHL/OdDHL)
Mean protease activity (mU/ml/OD600)b  SD
ExoS
Total protease Elastase Staphylolysin
AES-1
1 20 No  //// 60  14 0  0 88  0 
2 24 Yes  //// 35  4 0  0 1  1 
3 22 No  //// 1,244  188 367  168 18  6 
4 31 No  //// 28  17 5  6 2  3 
5 24 Yes  //// 51  24 5  2 2  1 
6 20 No  //// 66  18 12  10 2  0 
7 19 Yes  //// 1,024  103 75  53 0  0 
8 25 Yes  //// 830  115 42  12 0  0 
9 22 No  //// 1,232  50 81  61 16  0 
10 20 Yes  //// 1,205  70 171  121 51  13 
11 22 No  //// 17  5 22  17 1  0 
12 29 Yes  //// 129  19 107  98 1  1 
13 32 No  //// 1,157  46 135  17 3  0 
14 22 No  //// 160  16 24  14 5  3 
AES-2
15 18 No  //// 997  92 170  51 3  4 
16 28 No  //// 92  12 3  0 2  0 
17 29 No  //// 878  35 184  35 6  0 
18 26 No  //// 81  33 6  7 0  0 
19 37 Yes  //// 366  76 68  0 3  1 
Nonclonal
20 20 No  //// 1,198  84 282  57 81  0 
21 21 No  //// 699  259 73  23 88  2 
22 28 No  //// 857  47 53  21 9  3 
23 29 No  //// 0  0 0  0 2  0 
24 21 Yes  //// 1,346  74 91  5 31  0 
25 19 No  //// 784  78 149  137 91  100 
26 48 No  //// 901  351 53  59 2  3 
27 35 Yes  //// 74  77 0  0 2  1 
28 34 No  //// 1,082  26 98  29 69  1 
29 36 Yes  //// 66  9 0  0 1  0 
30 33 Yes  //// 0  0 0  0 2  1 
31 26 No  //// 78  16 7  9 3  0 
32 19 No  //// 0  0 0  0 5  3 
33 20 Yes  //// 935  30 155  31 4  1 
34 58 Yes  //// 49  18 8  22 2  1 
35 22 Yes  //// 90  70 10  14 2  0 
36 26 No  //// 818  34 52  74 29  0 
37 38 Yes  //// 47  52 7  10 7  5 
38 31 No  //// 13  1 0  0 3  0 
39 19 No  //// 0  0 16  13 2  1 
40 30 No  //// 873  100 51  25 61  1 
41 34 Yes  //// 0  0 0  0 5  1 
42 32 Yes  //// 0  0 0  0 9  12 
43 25 Yes  //// 77  9 0  0 3  3 
PAO1  //// 957  91 277  20 87  5 
a Composite AHL results for C. violaceum CV026 and A. tumefaciens A136 when bacteria were grown in TSB and in supplemented AB medium. Spots were
presumptively identified as representative of individual AHL molecules, following published results (47).
b One unit of enzyme activity was determined as the amount of activity required to change the final absorbance by 1.0 per ml of culture. Individual enzyme activities
were normalized to the OD600 of the culture at harvest. Mean values and standard deviations were determined across three experiments.
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methanol-water (60:40, vol/vol). Plates were overlaid with a thin film of TSB or
A agar seeded with either C. violaceum CV026 or A. tumefaciens A136 and
X-Gal (5-bromo-4-chloro-3-indolyl--D-galactopyranoside) (40 g/ml), respec-
tively. Short-chain AHLs (BHL and HHL) were detected by the production of
violacein by C. violaceum CV026, resulting in purple spots at the site of AHL
migration. Long-chain AHLs (OdDHL, N-3-oxodecanoyl-L-homoserine lactone
[ODHL], and N-3-oxohexanoyl-L-homoserine lactone [OHHL]) were detected
by the traG:lacZ/traR reporter in A. tumefaciens A136, inducing -galactosidase
expression and the development of blue/green dots at the site of AHL migration.
HHL was also detected using the A. tumefaciens reporter. The purified BHL,
HHL, and OdDHL used as positive controls were kindly supplied by Naresh
Kumar (Department of Chemistry, The University of New South Wales, Sydney,
Australia). It was reported previously that P. aeruginosa strains from lungs of CF
patients produce the highest amounts of long-chain AHL in AB medium con-
taining 0.2% glucose (12). Thus, bacteria that tested negative for long-chain
AHLs when grown in TSB medium were retested following culture in AB
medium supplemented with 0.2% glucose. All samples were tested at least three
times.
Statistical analyses. Pearson’s chi-square test was used to analyze the
secretion of the virulence factors and AHL molecules between clonal and
nonclonal groups. P values of 0.05 were considered to be significant. Rel-
ative risk (RR) and 95% confidence intervals (CIs) were used to determine
the strengths of the associations. The levels of virulence factor production
were analyzed using a standard t test for normally distributed data and using
the Mann-Whitney U test for nonparametric data. Relationships between
protease, elastase activity, and patient age were calculated using Pearson’s
correlation coefficient (r).
RESULTS
Mucoidy. The degree of mucoidy of the isolates was assessed
at isolation on horse blood agar by visual inspection and des-
ignated as negative, (low), (medium), or (high).
Forty-one of the 43 (95%) isolates were mucoid. Of these, nine
(21%) showedmucoidy, 25 (58%) showedmucoidy, and
seven (16%) showed  mucoidy (Table 1). All colonies of
each mucoid isolate were mucoid.
Presence of virulence factor and QS genes. All 43 isolates
produced bands of the predicted sizes in the vfr, rhlI, rhlR, lasA,
lasB, aprA, and rhlAB PCRs. One isolate (nonclonal) was neg-
ative for both lasI and lasR. The absence/mutation of both
genes was confirmed by dot hybridization. There was no evi-
dence of large-scale insertions or deletions within the ampli-
fied regions of any of the genes. All 43 samples were positive
for the exoS gene and negative for the exoU gene.
Exoprotease production. Thirty-seven of the 43 (86%) iso-
lates produced positive results in the total protease assay. Lev-
els were variable and in some cases very low (Table 1). SDS–
10% PAGE zymography produced a protease profile of up to
three bands for each sample (Fig. 2). Bands were detected at
molecular masses of approximately 120 kDa, 98 kDa, and 51
kDa. Elastase and staphylolysin were represented by bands at
120 kDa and 98 kDa, respectively, and alkaline protease was
represented by the band at 51 kDa (48). In some samples,
there were two bands at 51 kDa. Although the protease IV
enzyme has a molecular mass of 26 kDa, it aggregates under
mild SDS denaturing conditions and is resolved at a molecular
mass of 350 kDa (4). It was therefore barely detectable on the
10% zymograms used in this study. Twenty-four of the 43
(56%) isolates produced elastase/staphylolysin, and 22 of 43
(51%) isolates produced alkaline protease (Table 2). The
amount of protease secreted by individual isolates as indicated
by band intensity was variable. Thirty-two of the 43 (74%)
isolates exhibited elastase activity using the ECR assay. Levels
FIG. 1. DNA banding pattern following macrorestriction using a
rare-cutting restriction enzyme, SpeI, and PFGE analysis using our
previously described methods (1). Lanes 1, 2, and 3 are PAO1, AES-1,
and AES-2 controls, respectively. Lanes 4 to 10 represent P. aeruginosa
strains isolated from individual patients (Table 1). Lanes 5 to 8 have
unique banding patterns and hence represent nonclonal strains. Iso-
lates in lanes 9 and 10 (isolates 2 and 12) have a macrorestriction
pattern identical to that of AES-1, and lane 4 (isolate 15) is identical
to AES-2.
FIG. 2. Protease activity on 1% gelatin zymograms using 10% SDS-PAGE for AES-1 (isolates 9, 12, 14, and 2), AES-2 (isolates 15, 17, 18, and
19), and nonclonal strains (isolates 29, 30, 36, and 41) (Table 1). Up to three bands were detected, corresponding to molecular masses of 51, 98,
and 120 kDa. Bands at 98 and 120 kDa represented aggregate activity of elastase and staphylolysin, while the band at 51 kDa represented alkaline
protease. Isolates included in the figure are representative of isolates in each group. PAO1 was included as a control.
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ranged from 3 mU/ml to 367 mU/ml (Table 1). All 24 isolates
that produced elastase on zymography also showed elastase
activity in the ECR assay. Eight isolates that were negative by
zymography showed low levels of activity using the ECR assay.
As expected, there was a strong correlation between total pro-
tease and elastase activities (r	 0.847; P 0.001). Forty of the
43 (93%) isolates produced staphylolysin, but activities were
generally low, ranging from 1 mU/ml to 91 mU/ml (Table 1).
Chitinase activity and rhamnolipid production. Thirty-four
of the 43 (79%) isolates showed chitinase activity; levels
ranged from 6 mU/ml to 168 mU/ml (Table 2). Thirty-five of
the 43 (81%) isolates produced rhamnolipids (Table 2).
Exoenzyme S production. Thirty-three of the 43 (77%) iso-
lates grown in type III secretion system-inducing low-calcium
medium showed a single band of 36 kDa corresponding to the
ExoS protein on the Western blots. The intensities of the
bands were variable. Results for individual isolates are shown
in Table 1.
AHL production. When results from the two AHL biosen-
sors were combined, the number of spots varied from none to
five. Thirty-two of the 43 (74%) samples produced spots cor-
responding to one or more AHLs (Table 2). Using the reporter
strain C. violaceum CV026, two spots, most likely representing
BHL and HHL (12, 47), were noted. Thirty-one of the 43
(72%) isolates produced rhl-associated AHLs. Of these iso-
lates, 19 (44%) produced a spot corresponding to both HHL
and BHL (Fig. 3), and 12 (28%) had a spot corresponding to
HHL but not BHL. Spot densities and diameters varied among
isolates. Using the A. tumefaciens A136 reporter strain that
detects las-directed AHLs with a high degree of sensitivity
(37), up to four spots were detected, most likely corresponding
to OdDHL, ODHL, HHL, and OHHL (47). Following growth
in the TSB medium used previously in our microbial keratitis
study (47), at least one las-directed AHL was detected in 16
(37%) isolates. Of these isolates, OdDHL was detected in 8
isolates, ODHL was detected in 11 isolates, and OHHL was
detected in 6 isolates. Three additional isolates yielded OHHL
spots in assays using supplemented AB medium. The HHL
results using the A. tumefaciens A136 reporter were consistent
with those using the C. violaceum CV026 reporter. As ex-
pected, the isolate that tested negative for the lasI and lasR
genes had undetectable levels of AHL.
Overall relationships between phenotypic and patient char-
acteristics. Isolates with positive results for one or both rhl-
associated AHLs were significantly more likely to show total
protease (RR 	 1.7 [CI 	 1.0 to 2.7]; P 	 0.004) and elastase
(RR 	 5.8 [CI 	 1.6 to 20.6]; P 	 0.006) activities than those
testing negative for these AHLs. The levels in each case were
also significantly higher (both P  0.01). However, when the
las-directed AHL data were included, the associations between
AHL and protease production were no longer significant.
There were no relationships between the production of pro-
TABLE 2. Frequency of detection of virulence factors and AHLs in clonal and nonclonal isolates
Virulence factor
No. of isolates (%) Statistics (clonal vs nonclonal)
Total (n 	 43) Clonal (n 	 19) Nonclonal (n 	 24) P value RR (95% CI)
Total protease 37 (86) 19 (100) 18 (75) 0.019 1.3 (1.1–1.7)
ECR elastase 32 (74) 17 (89) 15 (63) 0.044 1.4 (1.0–2.0)
Zymography
Elastase/staphylolysin 24 (56) 14 (74) 10 (42) 0.036 1.8 (1.0–3.0)
Alkaline protease 22 (51) 14 (74) 8 (33) 0.009 2.2 (1.2–4.1)
Staphylolysin 40 (93) 16 (84) 24 (100) 0.079
Chitinase 34 (79) 16 (84) 18 (75) 0.461
Rhamnolipids 35 (81) 16 (84) 19 (79) 0.673
ExoS 33 (77) 16 (84) 17 (71) 0.302
AHL detection
rhl-directed AHLs 31 (72) 16 (84) 15 (63) 0.115
las-directed AHLs 16 (37) 7 (37) 9 (38) 0.965
At least one AHL 32 (74) 16 (84) 16 (67) 0.190
FIG. 3. Representative TLC analyses of AHLs produced by PAO1, AES-1 (isolates 6, 12, 4, and 14), AES-2 (isolates 16, 17, 15, and 18), and
nonclonal (isolates 29, 30, 36, and 39) (Table 1) P. aeruginosa isolates from the lungs of CF patients and purified BHL. AHLs were resolved from
unconcentrated supernatants using methanol-water, and representative spots were visualized with the biosensor C. violaceum (CV026). Up to two
dots were noted and identified as being BHL and HHL as shown. Isolates included in the figure are representative of all isolates in each group.
PAO1 and purified BHL were included as controls.
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teases or AHLs and exoenzyme S, rhamnolipids, and chitinase
and no association between mucoidy and other phenotypic
characteristics. There was a trend for decreasing protease and
elastase activity with increasing patient age, but the relation-
ship reached statistical significance for elastase only (r 	
0.34; P 	 0.03). Patient age may provide some indication of
the duration of infection. There were no relationships between
exacerbation and any of the phenotypic characteristics.
Clonal versus nonclonal groups. Data for AES-1 and AES-2
were combined for these analyses because of small numbers.
The male-to-female ratios in the combined clonal versus non-
clonal groups were similar, 9:10 and 12:12, respectively, as
were the mean ages (and age ranges), 25 (18 to 37) and 29 (19
to 58) years, respectively. A greater proportion of nonclonal
isolates produced  mucoidy than clonal isolates (7 of 24
versus 0 of 19), but proportions of isolates with mucoidy at
the  and  levels were similar between clonal and non-
clonal groups, and there was no overall relationship between
mucoidy and genotype. There was no significant difference in
the probability of having a clonal strain among patients with
exacerbation compared with those without (7 of 18 [39%]
versus 12 of 25 [48%]).
As shown in Table 2, clonal isolates were significantly more
likely than nonclonal isolates to produce proteases including
elastase, alkaline protease, and total protease. Clonal isolates
also tended to have greater total protease and elastase activi-
ties than nonclonal isolates, although the differences were not
statistically significant in this relatively small sample.
There was no difference in relationships between patient age
and total protease production in the clonal versus nonclonal
groups. Elastase levels were more likely to decrease with in-
creasing patient age in the nonclonal group (r 	 0.38; P 	
0.07) than in the clonal group (r 	 0.08, P 	 0.75), but this
relationship did not reach statistical significance. Clonal iso-
lates were also more likely to have at least one detectable AHL
and to exhibit BHLs/HHLs, but these trends did not reach
statistical significance. There were no relationships between
genotype and the production of ExoS, rhamnolipids, or chiti-
nase. Among the nonclonal group, there was a significant cor-
relation between elastase production and mucoidy (r 	 0.46;
P 	 0.03). This relationship was not evident in the clonal
group, but these findings should be interpreted with caution
because of the limited sample size and because mucoidy was
evaluated visually rather than by quantitation.
DISCUSSION
Our finding that the clonal strains were more likely to have
protease activity than nonclonal strains was of particular inter-
est. These results are consistent with those of our previous
study of protease IV activity using the same isolates (40). The
focus on proteases reflects previous reports that both the
United Kingdom CF LES (34) and an epidemic ocular P.
aeruginosa strain had increased protease activity (26). It there-
fore seems possible that genetically distinct clones of P. aerugi-
nosa from different environmental sources have evolved com-
mon mechanisms to facilitate spread and/or confer increased
virulence.
Nonetheless, the role of protease activity in transmissibility
or increased virulence in CF lung infection has not been es-
tablished. It was reported previously that specific antibodies
are produced against virulence factors such as the proteases in
the lung (18). Overall findings from the nonclonal group sup-
port current concepts that the progressive down-regulation of
proteases promotes long-term survival in lungs of CF patients.
Nonetheless, it is also clear from this and other studies that a
proportion of nonclonal isolates from well-established chronic
infections secrete proteases (some at a high level) (14, 24).
Conversely, some AES-1 and AES-2 isolates showed only low
protease activity. It is not known whether the lack of protease
activity affects the transmissibility or virulence of these isolates.
High protease activity has been linked with lung exacerbation
in some surveys (14, 19), but in the present study, there was no
relationship between protease activity and clinical state in ei-
ther the clonal or nonclonal group. One reason for the lack of
an association here may be that only one isolate from each
patient was tested. The protease activity of this isolate may not
have been representative of that of other phenotypes possibly
present (42). The link between high levels of mucoidy and
protease production noted in our nonclonal group was re-
ported previously (22).
It is not known whether AES-1 and AES-2 are generally less
susceptible to the processes that down-regulate proteases dur-
ing chronic infection than nonclonal strains or whether these
clones have undergone changes that allow the ongoing secre-
tion of these virulence factors over extended periods. There
was no evidence of major genetic changes within the amplified
regions of protease genes to correspond with the elastase size
variant identified in the ocular strain (26).
It is now widely accepted that proteases, like many other P.
aeruginosa virulence factors, are QS controlled. However, re-
lationships between protease activity and QS production dur-
ing chronic CF lung infection have not been clearly defined.
Several studies demonstrated the presence of P. aeruginosa
AHLs in CF lung secretions (5, 38), but there have been few
studies of AHL production in CF lung isolates. The results of
one recent small longitudinal series suggested that phenotypic
adaptations associated with chronic infection do not affect
either the nature or the amount of AHL produced (12). How-
ever, a comparative genomic analysis of two isolates of the
same strain from the same CF patient collected 8 years apart
revealed the development of mutations in lasR but not in the
rhlI and rhlR genes (39). In the present study, the majority of
isolates in both the clonal and nonclonal groups were positive
for the rhl-mediated BHLs/HHLs, but less than half had de-
tectable levels of las-directed AHL. Overall, there was a good
correlation between protease and AHL production; isolates
with undetectable AHL invariably produced very low or unde-
tectable levels of proteases, and conversely, very high total
protease activity (in excess of 900 mU/ml) was associated with
the presence of at least three AHLs.
Intriguingly, OdDHL and ODHL were not detected in any
AES-1 isolates even upon repeated testing under the growth
conditions that were previously reported to promote long-
chain AHL production (12). There was no evidence of major
genetic changes with the amplified regions of the lasI/lasR gene
to account for these findings. However, minor genetic changes
in the las signaling pathway have been linked with increased
protease expression in the United Kingdom LES (34) and with
changes in virulence factor expression in other studies (44). We
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speculate that in samples with undetectable levels of OdDHL,
protease activity is mediated by BHL/HHL in association with
the PQS system. PQS regulates the expression of lasB and, in
combination with BHL, has been shown to have a synergistic
effect on the expression of lasB compared with BHL or PQS
alone (28).
There was no evidence of any association between genotype,
ExoS, or rhamnolipid production or chitinase activity. As ex-
pected from previous studies, all 43 CF isolates (clonal and
nonclonal) had an invasive exoS phenotype (8, 25). However,
our finding that the majority of isolates had easily detectable
levels of ExoS in Western blots was surprising, since a loss of
type III effectors over the chronic phase of infection in the CF
lung has been widely reported (20, 25).
There have been few studies of rhamnolipid production or
chitinase activity in CF lung isolates. Rhamnolipids are a het-
erogeneous group of glycolipidic surface-active molecules
thought to have multiple virulence activities related mainly to
their surfactant properties (41). Rhamnolipids promote early
infiltration of airway epithelia (49) and may have a central role
in biofilm architecture (6). The role of chitinase in lung infec-
tion is unknown. The lack of association between rhamnolipids
or chitinase production and protease activity was not surpris-
ing. However, since rhamnolipids and chitinase have been re-
ported to be QS controlled (9, 41), the production of these
virulence factors in a small proportion of samples without
detectable AHL could reflect the complexities of virulence
factor-regulatory mechanisms or the presence of a mutation(s)
leading to the decoupling of normal regulation.
Our comparisons of the phenotypic characteristics of clonal
and nonclonal strains extend the general understanding of the
pathobiology of P. aeruginosa infection in the CF lung. How-
ever, the major aim of this study was to gain insight into the
properties that distinguish clonal from nonclonal P. aeruginosa
strains in CF. Our findings support evidence from studies of
other clonal P. aeruginosa strains showing that protease activity
may mediate increased infectivity and/or virulence. Advances
in the understanding of the properties underpinning the in-
creased infectivity of epidemic P. aeruginosa strains are critical
to the development of new therapeutics to treat infected pa-
tients and strategies to prevent transmission. Key traits may
also serve as targets for vaccines. Findings may also be relevant
for non-CF bronchiectasis, for the immunocompromised, and
for intensive care and burn units, where clonal P. aeruginosa is
also a problem.
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